

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* WEAVER GREGORY L (Last) (First) (Middle) C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET (Street) SEATTLE WA 98104 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol ATOSSA THERAPEUTICS, INC. [ATOS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/02/2021	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/02/2021		M		4,581	A	\$5.64	4,581	D	
Common Stock	07/02/2021		M		45,000	A	\$2.38	49,581	D	
Common Stock	07/02/2021		M		45,000	A	\$2.52	94,581	D	
Common Stock	07/02/2021		M		70,000	A	\$1.7	164,581	D	
Common Stock	07/02/2021		F		57,084	D	\$6.4 ⁽¹⁾	107,497	D	
Common Stock	07/02/2021		S		107,497	D	\$5.58 ⁽²⁾	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$5.64	07/02/2021		M			4,581	(3)	(3)	Common Stock	4,581	\$0	0	D	
Stock Option (right to buy)	\$2.38	07/02/2021		M			45,000	(4)	(4)	Common Stock	45,000	\$0	0	D	
Stock Option (right to buy)	\$2.52	07/02/2021		M			45,000	(5)	(5)	Common Stock	45,000	\$0	0	D	
Stock Option (right to buy)	\$1.7	07/02/2021		M			70,000	(6)	(6)	Common Stock	70,000	\$0	0	D	

Explanation of Responses:

- Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021.
- Reflects the weighted average sale price. The range of prices for such transaction is \$5.51 to \$5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
- These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
- These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
- These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date.

/s/ Gregory L. Weaver 07/07/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.